Survival comparison between glioblastoma multiforme and other incurable cancers

Journal of Clinical Neuroscience

Volumn 17, Issue 4, 2010, Pages 417-421

  Tran, B ^a   Rosenthal, M A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Chemotherapy; Glioblastoma multiforme; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS;

EID: 77349117235     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.09.004     Document Type: Review

References (23)

1. Walker M.D., Alexander Jr. E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 (1978) 333-343
2. Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. J Clin Oncol 19 (2001) 509-518
3. Stupp R., Mason W., Van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
4. Mirimanoff R., Mason W., Van den Bent M.J., et al. Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolamide versus RT alone. J Rad Oncol Biol Phys 69 Suppl. (2007) S2
5. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 (2009) 459-466
6. AIHW (Australian Institute of Health and Welfare) and AACR (Australasian Association of Cancer Registries). Cancer in Australia: an overview, 2006. Cancer series no. 37. Cat. no. CAN 32. Canberra: Australian Institute of Health and Welfare; 2007.
7. Horner MJ, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute. ; 2008 [accessed 30.04.08].
8. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17 (2000) 3068-3077
9. von der Masse H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
10. Piccart-Gebhart M.J., Burzykowdki T., Buyse M., et al. Taxanes alone or in combination with anthracyclines as first line therapy of patients with metastatic breast cancer. J Clin Oncol 26 (2008) 1980-1986
11. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med 344 (2001) 783-792
12. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26 (2008) 2013-2019
13. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer. N Engl J Med 350 (2004) 1-8
14. Vermorken J.B., Mesia R., Rivera F., et al. Platinum based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008) 1116-1128
15. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
16. Scagliotti G.V., Parkh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naïve patients with advanced stage non-small-cell lung cancer. J Clin Oncol 26 (2008) 1-11
17. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22 (2004) 1118-1125
18. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
19. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358 (2008) 36-46
20. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynaecologic oncology group study. J Clin Oncol 21 (2003) 3194-3200
21. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 25 (2007) 1960-1966
22. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal-cell carcinoma. J Clin Oncol 27 (2009) 3584-3590
23. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512